Benign ยท Apocrine adnexalICD-10 D23

Cylindroma

Dermal eccrine cylindroma; "turban tumour" (when multiple confluent on the scalp)

Cylindroma is a benign adnexal tumour with apocrine differentiation, classically presenting as a solitary, firm, pink-red dermal nodule on the scalp, head or neck of an adult. The far more characteristic clinical scenario is that of multiple cylindromas โ€” pathognomonic of Brooke-Spiegler / CYLD cutaneous syndrome โ€” accumulating over the scalp, face and trunk over decades and producing the disfiguring confluent "turban tumour" appearance from which the older name derives. Although themselves benign, long-standing cylindromas โ€” particularly in the syndromic context โ€” can undergo malignant transformation to cylindrocarcinoma, signalled by abrupt growth, ulceration or pain. Histology shows characteristic basaloid lobules in a "jigsaw" / "Chinese-puzzle" pattern with surrounding hyaline basement-membrane material.

CurrentLast reviewed 26 April 2026
Clinical image of Cylindroma
Cylindroma. Image sourced from DermNet New Zealand. Used under CC BY-NC-ND 4.0. No endorsement implied.

Clinical features

  • Solitary cylindroma โ€” single, firm, smooth, pink-red dermal nodule, typically 1โ€“3 cm; head, scalp, neck of an adult.
  • Multiple cylindromas โ€” dozens to hundreds of nodules accumulating over decades on the scalp, face, neck and trunk; confluence on the scalp produces the classical disfiguring "turban tumour" appearance.
  • Onset typically late adolescence to early adulthood; progressive accumulation through life.
  • F>M (~9:1).
  • Asymptomatic; cosmetic concern, alopecia and (rarely) bleeding from larger lesions are the main issues.
  • Associated tumours in syndromic patients โ€” spiradenomas (often painful, blue-grey nodules) and trichoepitheliomas (face); see Brooke-Spiegler syndrome.

Histology

  • Well-circumscribed dermal proliferation of basaloid cell lobules in a characteristic "jigsaw" / "Chinese-puzzle" pattern.
  • Each lobule is surrounded by a thick eosinophilic, PAS-positive, basement-membrane-like hyaline rim.
  • Two cell populations within each lobule:
    • Outer small dark basaloid cells.
    • Inner larger pale ductal cells.
  • Hyaline droplets within the lobules.
  • No atypia, no mitoses, no necrosis in benign cylindroma.
  • Cylindrocarcinoma โ€” malignant transformation; characterised by loss of the dual cell population, atypia, mitoses, necrosis, infiltrative growth.
  • Differential: spiradenoma (overlapping; combined "spiradenocylindroma" common), basal cell carcinoma (lacks hyaline rim, no dual cell population), adenoid cystic carcinoma of skin.

Malignant transformation

  • Lifetime risk in solitary cylindroma is very low.
  • In Brooke-Spiegler syndrome, the cumulative risk of malignant transformation in one of the multiple cylindromas / spiradenomas is estimated 5โ€“10%.
  • Warning signs:
    • Abrupt growth in a previously stable nodule.
    • Ulceration.
    • Pain.
    • Bleeding.
    • Discharge.
    • Fixity to deeper tissues.
  • Any change should prompt biopsy and re-staging.

Management

  • Solitary or symptomatic cylindromas โ€” excisional surgery with full histology; modest margin sufficient.
  • Multiple lesions / "turban tumour" disease:
    • Staged excision of individual lesions for symptoms or cosmesis.
    • For extensive scalp involvement โ€” total scalp excision and reconstruction with split-thickness skin graft, tissue expander or free flap (specialist plastic surgery centre); see scalp reconstruction.
    • Emerging targeted topical therapy โ€” case reports of topical sirolimus and topical tropomyosin receptor kinase inhibitors.
  • Annual full-skin review; biopsy of any changing lesion to exclude cylindrocarcinoma.
  • Refer to clinical genetics for CYLD testing if multiple lesions or family history; cascade testing โ€” see Brooke-Spiegler syndrome.

References

  1. Rajan N et al. The genetics and management of CYLD cutaneous syndrome. Br J Dermatol; 2020.
  2. Massoumi R, Paus R. Cylindromatosis and the CYLD gene โ€” biology, clinical features and treatment options. Arch Dermatol Res; 2007.

Spot a correction?

If any clinical statement, citation or link on this page needs updating, please email admin@skinoncology.net with the page name, the proposed correction and the supporting source.